来自官方财务报表的收入、利润与现金流历史。
Corcept Therapeutics Incorporated 是一家生物制药公司，在美国从事治疗严重内分泌、肿瘤、代谢和神经系统疾病的药物的发现和开发。该公司提供 Korlym，一种口服药物，用于治疗患有内源性库欣综合征的成年患者继发于皮质醇增多症的高血糖，这些患者患有 2 型糖尿病或葡萄糖不耐症，并且手术失败或不适合手术。它还开发了 relacorilant，一种针对皮质醇增多症患者的选择性皮质醇调节剂；一种选择性皮质醇调节剂 miricorilant，目前正处于治疗代谢功能障碍相关脂肪性肝炎的 1b 期试验中；以及一系列专有的选择性皮质醇调节剂，例如用于治疗卢伽雷氏病的 relacorilant、nenocorilant、miricorilant 和 dazucorilant。该公司成立于 1998 年，总部位于加利福尼亚州雷德伍德城。
机器翻译
| 利润表 | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 总收入 | $831M | $761M | $675M | $482M | $402M | $366M | $354M | $306M | $251M | $159M | $81M | $50M | $27M | $10M | $3M | $0M | — | $0M | $0M | $0M | $0M |
| 毛利 | $817M | $748M | $664M | $476M | $396M | $361M | $348M | $301M | $246M | $156M | $79M | $49M | $26M | $10M | $3M | $0M | — | $0M | $0M | $0M | $0M |
| 毛利率% | 98.3% | 98.3% | 98.4% | 98.7% | 98.7% | 98.6% | 98.4% | 98.2% | 97.9% | 97.8% | 97.5% | 97.3% | 96.7% | 98.6% | 97.2% | — | — | 100.0% | 100.0% | 100.0% | 100.0% |
| 营业利润（EBIT） | $6M | $45M | $137M | $107M | $113M | $124M | $128M | $112M | $89M | $53M | $10M | ($3M) | ($28M) | ($41M) | ($36M) | ($32M) | ($27M) | ($20M) | ($20M) | ($12M) | ($26M) |
| 营业利润率% | 0.8% | 5.9% | 20.3% | 22.2% | 28.0% | 34.0% | 36.2% | 36.4% | 35.6% | 33.2% | 12.5% | -6.9% | -104.0% | -400.7% | -1096.8% | — | — | -69827.6% | -9420.6% | -2540.5% | -8701.4% |
| 净利 | $55M | $100M | $140M | $106M | $101M | $113M | $106M | $94M | $75M | $129M | $8M | ($6M) | ($31M) | ($46M) | ($38M) | ($32M) | ($26M) | ($20M) | ($20M) | ($12M) | ($25M) |
| 净利润率 % | 6.6% | 13.1% | 20.7% | 22.0% | 25.2% | 30.7% | 30.0% | 30.7% | 30.0% | 81.1% | 10.0% | -12.7% | -118.2% | -444.2% | -1150.5% | — | — | -69537.9% | -9598.6% | -2401.0% | -8460.2% |
| EBITDA | $23M | $68M | $163M | $126M | $116M | $128M | $130M | $114M | $90M | $53M | $10M | ($3M) | ($27M) | ($41M) | ($36M) | ($32M) | ($26M) | ($20M) | ($20M) | ($12M) | ($26M) |
| 每股收益（EPS） | $0.42 | $0.83 | $1.23 | $0.95 | $0.87 | $0.89 | $0.85 | $0.77 | $0.60 | $1.04 | $0.07 | $-0.06 | $-0.31 | $-0.46 | $-0.41 | $-0.39 | $-0.38 | $-0.38 | $-0.43 | $-0.34 | $-1.09 |
| 已发行股数 (M) | 118M | 120M | 113M | 112M | 116M | 126M | 124M | 123M | 127M | 125M | 116M | 107M | 101M | 100M | 93M | 83M | 68M | 52M | 47M | 34M | 23M |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 CORT 交互式查看器。 /companies/us/CORT
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms